About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 10652 record(s)
Req # A-2022-000704
All correspondence between Health Canada officials and Dr. Daniel Myran from January 1, 2022 and August 26, 2022 regarding Dr. Daniel Myran.Organization: Health Canada
March 2024
Req # A-2022-000798
Health Canada issued a Request for Information (RFI) to Industry regarding the Canadian Dental Care Plan (CDCP) currently in development. Interested suppliers were to provide a response summited through the Electronic Procurement Solution (EPS). All RFI responses Health Canada received between when the RFI was issued and August 22, 2022.Organization: Health Canada
March 2024
Req # A-2022-001043
Relating to the investigation of the "New Brunswick neurological syndrome of unknown cause", all documents and all other correspondence from anyone within the department and/or under its influence or control between January 01, 2017 and October 31, 2022.Organization: Health Canada
March 2024
Req # A-2022-001122
All records that involve Egale Canada Human Rights Trust and Egale Canada, from December 2019 to December 2022.Organization: Health Canada
March 2024
Req # A-2022-001389
The disclosable inspection document(s) listing the Inspector’s detailed observations, conditions found, and any follow-up expected by Health Canada for the human drugs drug establishment licence Good Pharmacovigilance Pratices (GVP) inspection of the Johnson & Johnson facility (Site B) located on McNabb St, Markham, Ontario starting around 7 February 2022. Reference Number 502933.Organization: Health Canada
March 2024
Req # A-2022-001508
Any briefing notes, discussion papers, reports or presentations done in 2022 on best practices of the healthcare systems of other countries compared to those in Canada.Organization: Health Canada
March 2024
Req # A-2023-000309
All correspondence between Minister Jean-Yves Duclos or his staff, including Deputy Minister Dr. Stephen Lucas and Chief of Staff Jamie Kippen and Public Health Agency of Canada (PHAC) officials and any outside Non Government Organizations (NGO) regarding patients in New Brunswick enduring neurological conditions and a public health investigation from January 01, 2023 to May 31, 2023.Organization: Health Canada
March 2024
Req # A-2023-000584
With respect to generic drug i Health Canada's list of "Generic Drug Submissions Under Review" dated 2022-01-19 for the medicinal ingredient liraglutide, any document that would indicate the current status of the submission, such as but not limited to, an Acknowledgment Letter, Notice of Defiency (NOD), Notice of Non-Compliance (NON), NOD-Withdrawal (NOD-W), NOD-Withdrawal (NOD-W), or sponsor's letter requesting cancellation of their submission.Organization: Health Canada
March 2024
Req # A-2023-000589
All notes made by the Health Canada employees who reviewed the Pfizer-BioNTech Comirnaty COVID-19 vaccine, in relation to the review, that were made during the reviewal process of the drug. Date Range: January 1, 2020 to July 31, 2020.Organization: Health Canada
March 2024
Req # A-2023-000605
All notes made by the Health Canada employees who reviewed the Novavax Nuvaxovid COVID-19 vaccine, in relation to the review, that were made during the reviewal process of the drug. Date Range: August 1, 2020 to December 31, 2020.Organization: Health Canada
March 2024